Scientific Rep (2025) 15:1
Finally, in obese diabetic individuals, the GLP-1R/GIPR/GcgR tri-agonist may be the most appropriate option, having the greatest potential to improve metabolism by weight-dependent and -independent mechanisms
Most people will miss it entirely, and it looks intentional
Building on the understanding that GLP-1 agonists induce weight loss through appetite suppression and slowed gastric emptying, it is crucial to recognize the potential downstream consequences of these mechanisms, particularly regarding nutritional status
But there's been an explosion in popularity around peptides marketed for injury recovery like BPC-157 and TB-500
"The notion that you can go off it in six months, this so-called quick-start approach, is not really how obesity is treated